<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7237904\results\search\disease\results.xml">
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="applicable for combating COVID-19 [1], because it is a new" exact="disease" post="that only emerged in December 2019 and has already"/>
  <result pre="These agents have been shown to be effective in other" exact="disease" post="indications that appear to share some similar pathophysiological pathways"/>
  <result pre="some evidence from cell culture models showing inhibition of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [2], the causative"/>
  <result pre="evidence from cell culture models showing inhibition of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) infection [2], the causative agent"/>
  <result pre="from cell culture models showing inhibition of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) infection [2], the causative agent of"/>
  <result pre="showing inhibition of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)" exact="infection" post="[2], the causative agent of COVID-19. Inadequate preclinical studies"/>
  <result pre="risk of failure in clinical trials. For example, sofosbuvir, targeting" exact="hepatitis C" post="virus RNA-dependent RNA polymerase (RdRp), was shown to inhibit"/>
  <result pre="C virus RNA-dependent RNA polymerase (RdRp), was shown to inhibit" exact="hepatitis E" post="virus (HEV) in cell culture model by one experimental"/>
  <result pre="demonstrated that sofosbuvir was unable to cure any patients with" exact="chronic" post="HEV infection [5]. Recent in silico molecular docking has"/>
  <result pre="sofosbuvir was unable to cure any patients with chronic HEV" exact="infection" post="[5]. Recent in silico molecular docking has indicated that"/>
  <result pre="emerged novel coronavirus (2019-nCoV) in vitroCell Res.30202026927132020029 3.Dao ThiV.L.Sofosbuvir inhibits" exact="hepatitis E" post="virus replication in vitro and results in an additive"/>
  <result pre="additive effect when combined with ribavirinGastroenterology1502016828526408347 4.KamarN.Direct-acting antiviral therapy for" exact="hepatitis E" post="virus?Lancet Gastroenterol. Hepatol.22017154155 5.CornbergM.Efficacy and safety of sofosbuvir monotherapy"/>
  <result pre="Hepatol.22017154155 5.CornbergM.Efficacy and safety of sofosbuvir monotherapy in patients with" exact="chronic hepatitis" post="E-The HepNet SofE pilot studyJ. Hepatol.702019E129E130 6.ElfikyA.A.Anti-HCV, nucleotide inhibitors,"/>
  <result pre="5.CornbergM.Efficacy and safety of sofosbuvir monotherapy in patients with chronic" exact="hepatitis" post="E-The HepNet SofE pilot studyJ. Hepatol.702019E129E130 6.ElfikyA.A.Anti-HCV, nucleotide inhibitors,"/>
 </snippets>
</snippetsTree>
